Search for: "Pfizer, Inc. (Pfizer)"
Results 1461 - 1480
of 1,505
Sorted by Relevance
|
Sort by Date
16 Aug 2009, 11:23 am
The best example of the downside of optionality was the sale of United Rentals Inc. where the buyer, Cerberus, unabashedly chose to pay the break fee rather than close, despite the absence of any material problem in the URI business. [read post]
6 Feb 2013, 9:00 pm
Then later in the summer, the DOJ moved to a 9 point compliance program in the Pfizer DPA. [read post]
15 Sep 2011, 4:06 am
Co., Inc., 480 Pa. 547, 559, 391 A.2d 1020, 1027 (1978). [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
1 Feb 2008, 12:00 am
: (IPBiz),State of the Union address 28 Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O),Alnylam Pharmaceuticals secures UK patent covering molecules that affect RNA interference: (SmartBrief),Doha style compulsory licences for exports: The politics…: (Spicy IP),Pushing to compulsory licensing: Pharma companies heading closer to Doha: (Spicy IP),Financial Express on the battle between big pharma companies and the generic… [read post]
4 Nov 2021, 5:37 am
I'm putting up some excerpts from my new draft article, The Law of Pseudonymous Litigation, hoping to get some feedback. [read post]
3 May 2014, 8:56 am
Pfizer, Inc., 196 F. [read post]
12 Nov 2017, 11:00 pm
A recurring issue in securities cases involves the question of when plaintiffs may rely on the presumption of reliance under the fraud on the market doctrine. [read post]
13 Jun 2013, 7:05 pm
Apple Inc. 12-1158Issue: (1) Whether the offer for sale and/or sale of a product that embodies a patented invention can directly infringe a method claim under 35 U.S.C. [read post]
18 Jan 2007, 7:53 pm
Pfizer Inc., No. [read post]
30 Aug 2016, 2:33 pm
Wyeth, Inc., Dr. [read post]
2 Aug 2014, 6:05 am
Sinai Hospital and Medical Center of Chicago, Inc., 807 N.E.2d 1026, 1033 (Ill. [read post]
7 Jun 2007, 10:52 am
Pfizer, Inc., 198 F. [read post]
23 Jan 2013, 1:02 am
., Inc. v. [read post]
23 Jan 2013, 1:02 am
., Inc. v. [read post]
27 Sep 2007, 11:38 am
Pfizer, Inc., 2004 WL 2191804, *4 & n.4 (S.D. [read post]
9 May 2007, 1:34 pm
"The Draft continues to use the "carve at the joint" metaphor from In re Rhone-Poulenc Rorer, Inc., 51 F.3d 1293 (7th Cir. 1995) (e.g., §2.03, comment c & Reporters' Notes) to justify widespread issue certification, even though Rhone-Poulenc used that phrase not in support of issue certification, but to caution against bifurcating a trial in a way that would have different juries examining the same issue in violation of the Seventh Amendment. 51 F.3d… [read post]
15 Mar 2007, 2:12 am
Other pharmaceutical companies that have filed WIPO cases in the past include Pharmacia & Upjohn (in relation to Rogaine), American Home Products, McNeil Consumer Brands (Tylenol), Pfizer (Viagra), Merck, Sanofi-Aventis (Ambien), CVS Pharmacy, Lilly ICOS, Valeant, and Bayer. [read post]
20 Mar 2008, 10:29 am
Pfizer, Inc., 2006 WL 2819046, at *3 (D.N.J. [read post]
27 Nov 2012, 2:00 am
Now, according to Studley, Inc., the average is down to 225 square feet. [read post]
